314: JD Vance's Biotech Ties, Cassava Resignations, And Insulin Shortages The Readout Loud podcast

Artwork

Indhold leveret af STAT. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af STAT eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

The Readout Loud « »
314: JD Vance's biotech ties, Cassava resignations, and insulin shortages

2M ago 33:02

Del

MP3•Episode hjem

Indhold leveret af STAT. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af STAT eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.

… continue reading

324 episoder

#Business #Stats

Artwork

314: JD Vance's biotech ties, Cassava resignations, and insulin shortages

The Readout Loud

published 2M ago

Del

MP3•Episode hjem

Indhold leveret af STAT. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af STAT eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.

… continue reading

324 episoder

#Business #Stats

Alle episoder

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner